GlycoMimetics (GLYC) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
GlycoMimetics Reports Third Quarter 2019 Financial Results and Recent Operational Developments
November 7, 2019 8:24 AM ESTAdvanced its Phase 3 program for uproleselan in acute myeloid leukemia (AML) through both Company-sponsored and NCI-sponsored clinical trials Announced abstracts accepted for presentation in December at the Annual Meeting of the American Society of Hematology (ASH) in Orlando, which continue to demonstrate key role of E-selectin ligand and potential value of uproleselan in AML Announced that Pfizers Phase 3 clinical trial evaluating rivipansel in sickle cell disease (SCD) failed to meet the primary endpoint and key secondary endpoints Eliminated certain non-core research and development spending commitments
... More
